Oral anticoagulants (OACs) are commonly used to reduce the risk of venous
thromboembolism and the risk of stroke in patients with atrial fibrillation. Endorsed by the …

ABSTRACT Introduction Neuropsychiatric disorders (NPDs)(neurodevelopmental, mental,
neurodegenerative, neurotoxic, complex disorders) are the third major problem of health in …

Background Investigations into the rivaroxaban response from the perspective of genetic
variation have been relatively recent and wide in scope, whereas there is no consensus on …

Platelet function testing (PFT) could be a useful clinical tool to guide individualized
antithrombotic treatment in patients with atrial fibrillation (AF) undergoing percutaneous …

If atrial fibrillation (AF) and acute coronary syndrome (ACS) coexist, they should be treated
with combined antithrombotic therapy. To reduce the risk of bleeding while maintaining the …

Hemorrhage events occur most frequently in anticoagulant therapy for non‐valvular atrial
fibrillation (NVAF). Rivaroxaban is used widely for routine anticoagulation care. Genetic …

Aims This letter to the editor features a selection of possible miRNAs to be included into
further development of smart diagnostic systems for clopidogrel resistance testing. Materials …

This meta‐analysis aimed to investigate the effect of the genotype on the pharmacokinetics
and bleeding events of direct oral anticoagulants (DOACs) and comprehensively searched …

Objectives The aim of this study is to assess micro-RNAs miR-142 and miR-39 as potential
biomarkers for drug-monitoring of rivaroxaban among elderly patients with atrial fibrillation …

Pharmacogenomics has a potential to improve and individualize treatment of cardiovascular
diseases. In the past couple of decades, strong evidence emerged to inform PGx guided …